SCHEMBL172911

SCHEMBL172911

COc1ccc2c(c1)C(=O)CO2

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.63
KDM4E B2RXH2 4/20 0.63
ALDH1A1 P00352 4/20 0.63
NPC1 O15118 3/20 0.63
RAB9A P51151 3/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
GAA P10253 2/20 0.63
HPGD P15428 1/20 0.63
ALOX12 P18054 1/20 0.63
TDP1 Q9NUW8 1/20 0.63
HSD17B10 Q99714 3/20 0.55
CYP2C9 P11712 2/20 0.55
MEN1 O00255 1/20 0.55
CYP1A2 P05177 1/20 0.55
PKM P14618 1/20 0.55
CYP2C19 P33261 1/20 0.55
KMT2A Q03164 1/20 0.55
ABCB1 P08183 1/20 0.52
AR P10275 1/20 0.52
ABCG2 Q9UNQ0 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4055987 0.87 NPC1 (0.57) MAPTKDM4EALDH1A1NPC1RAB9A
SCHEMBL68899 0.86 MAPT (0.59) MAPTKDM4EALDH1A1SMN1; SMN2HSD17B10
SCHEMBL31689707 0.86 MAPT (0.59) MAPTKDM4EALDH1A1SMN1; SMN2HSD17B10
SCHEMBL26767783 0.85 MAPT (0.52) MAPTKDM4EALDH1A1NPC1RAB9A
SCHEMBL769313 0.83 NPC1 (0.54) MAPTKDM4EALDH1A1NPC1RAB9A
SCHEMBL29814619 0.80 NPC1 (0.52) MAPTKDM4EALDH1A1NPC1RAB9A
SCHEMBL29817556 0.80 ALDH1A1 (0.65) MAPTKDM4EALDH1A1NPC1RAB9A
SCHEMBL28827715 0.80 ALDH1A1 (0.65) MAPTKDM4EALDH1A1NPC1RAB9A
SCHEMBL8029261 0.80 NPC1 (0.52) MAPTKDM4EALDH1A1NPC1RAB9A
SCHEMBL87317 0.80 ALDH1A1 (0.83) MAPTKDM4EALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119528857-A Synthesis method of 5-methoxy-3-benzofuranone 上海毕臣生化科技有限公司 2025-02-28 CN claimed
US-20250122213-A1 OPIOID RECEPTOR MODULATORS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-04-17 US disclosed
CN-119528857-A Synthesis method of 5-methoxy-3-benzofuranone 上海毕臣生化科技有限公司 2025-02-28 CN disclosed
CN-119528857-A Synthesis method of 5-methoxy-3-benzofuranone 上海毕臣生化科技有限公司 2025-02-28 CN disclosed
CN-119528857-A Synthesis method of 5-methoxy-3-benzofuranone 上海毕臣生化科技有限公司 2025-02-28 CN disclosed
US-12195478-B2 Opioid receptor modulators THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-01-14 US disclosed
EP-4487913-A2 OPIOID RECEPTOR MODULATORS The Trustees Of Columbia University In The City Of New York (US) 2025-01-08 EP disclosed
EP-3224261-B1 OPIOID RECEPTOR MODULATORS UNIV COLUMBIA (US) 2024-09-18 EP disclosed
WO-2024146619-A1 AURONE DERIVATIVE OR ANALOG, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 中国科学院上海药物研究所 2024-07-11 WO disclosed
CN-118307504-A Orange ketone derivative or analogue, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2024-07-09 CN disclosed
WO-2004099191-A2 BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIB ITORS WYETH (US) 2004-11-18 WO disclosed
WO-2003093258-A2 NOVEL SPIRO KETONE AND CARBOXYLIC ACID DERIVATIVES AS SPECIFIC INHIBITORS FOR (PO3H2) SER/(PO3H2)THR-PRO-SPECIFIC PEPTIDYL-PROLYL-CIS/TRANS-ISOMERASES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2003-11-13 WO disclosed
US-6147110-A MELATONINERGIC AGENTS; SLEEP, EATING, CENTRAL NERVOUS SYSTEM, AND CARDIOVASCULAR DISORDERS ADIR ET COMPAGNIE (FR) 2000-11-14 US disclosed
US-6071946-A FOR TREATING DISORDERS OF THE MELATONINERGIC SYSTEM, SLEEP DISORDERS, CIRCADIAN RHYTHM DISORDERS ADIR ET COMPAGNIE (FR) 2000-06-06 US disclosed
US-5998461-A SLEEP DISORDERS ADIR ET COMPAGNIE (FR) 1999-12-07 US disclosed
EP-0926145-A1 Napthalene compounds, method for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1999-06-30 EP disclosed
US-RE32196-E PROPHYLACTIC CHEMOTHERAPY OF ALLERGIC CONDITIONS LILLY INDUSTRIES LIMITED (GB) 1986-07-01 US disclosed
US-4259340-A PROPHYLACTIC CHEMOTHERAPY OF ALLERGIC CONDITIONS SUCH AS ASTHMA LILLY INDUSTRIES LIMITED (GB) 1981-03-31 US disclosed
US-4185110-A ANTIALLERGENS CIBA-GEIGY CORPORATION (US) 1980-01-22 US disclosed
US-3961952-A ELECTROPHOTOGRAPHY, SUPPORTS, COATINGS ITEK CORPORATION (US) 1976-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12195478-B2 Opioid receptor modulators OPRM1, OPRL1, OPRD1 MAPT 3739/4885KDM4E 1372/4885ALDH1A1 2316/4885
US-20250122213-A1 OPIOID RECEPTOR MODULATORS OPRM1, OPRL1, OPRD1 MAPT 3739/4885KDM4E 1372/4885ALDH1A1 2316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.